Can iron excess worsen porphyria cutanea tarda?

Porphyria cutanea tarda (PCT) is a metabolic disorder characterized by cutaneous lesions and systemic porphyrin accumulation, heavily influenced by hepatic iron status.

Mechanistic pathways

• ROS generation: Excess hepatic iron participates in Fenton chemistry, producing reactive oxygen species (ROS) that induce severe oxidative stress within hepatocytes.
• Enzymatic inhibition: This oxidative environment oxidizes uroporphyrinogen into uroporphomethene. Uroporphomethene acts as a potent, iron-dependent inhibitor that binds to and reduces functional uroporphyrinogen decarboxylase (UROD) activity.
• Porphyrin accumulation: The resulting blockade of UROD prevents the normal decarboxylation process, leading to a massive accumulation of highly carboxylated porphyrins in the liver.

Clinical implications

• Cutaneous pathology: Excess porphyrins enter the systemic circulation and deposit in the skin. Upon UV light exposure, these molecules trigger phototoxicity, complement activation, and cell damage, worsening cutaneous fragility and blistering.
• Treatment efficacy: This pathway explains the clinical success of iron-reduction therapies, such as therapeutic phlebotomy, which decrease hepatic iron stores, alleviate oxidative stress, and restore functional UROD activity to resolve symptoms.

Bottom line

• Hepatic iron excess drives PCT pathogenesis by promoting ROS-mediated generation of uroporphomethene, which directly inhibits UROD, leads to systemic porphyrin accumulation, and causes severe cutaneous phototoxicity.